Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Oct;97(43):e12732.
doi: 10.1097/MD.0000000000012732.

On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study

Affiliations
Randomized Controlled Trial

On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study

Joon Hyun Cho et al. Medicine (Baltimore). 2018 Oct.

Abstract

Background and aims: No consensus has been established regarding optimal long-term maintenance therapy in symptomatic gastroesophageal reflux disease (GERD). The aim of this study was to compare the efficacies of on-demand and continuous therapy with esomeprazole as maintenance treatments for GERD.

Methods: Patients with upper gastrointestinal (GI) endoscopy-proven GERD who received initial proton pump inhibitor (PPI) therapy for 8 weeks were randomized to an on-demand group (esomeprazole 40 mg) or a continuous group (esomeprazole 20 mg). Intensities and frequencies of heartburn and acid regurgitation were assessed using a 6-point Likert scale (0 = no symptoms; 5 = very severe symptoms) and a 6-point frequency scale (0 = none; 5 = symptoms for > 5 days per week) at baseline (start of maintenance treatment) and after 12 weeks of treatment. Alleviation of symptoms was quantified using percentages of patients with a Likert scale or frequency scale of 0 or 1.

Results: Of the 88 patients enrolled, 8 patients were excluded due to follow-up loss in early period of this study, and finally, 39 in the on-demand group and 41 in the continuous group were analyzed. No significant intergroup difference was found between Likert scale or frequency scale of heartburn or regurgitation at baseline. Percentages of symptom alleviations in the on-demand and continuous groups for intensity of heartburn were 56.4%/48.8% at baseline (P = .523) and 82.1%/87.8% at 12 weeks (P = .471), for frequency of heartburn were 61.5%/46.3% at baseline (P = .173) and 76.9%/87.8% at 12 weeks (P = .200), for intensity of regurgitation was 53.8%/43.9% at baseline (P = .374) and 82.1%/87.8% at 12 weeks (P = .471), and for frequency of regurgitation was 61.5%/56.1% at the baseline (P = .621) and 82.1%/82.9% at 12 weeks (P = .918), respectively. Furthermore, no significant intergroup difference was found for convenience of medication or subjective satisfaction.

Conclusions: Intensities and frequencies of heartburn and regurgitation responded well to maintenance treatment in patients in the on-demand and continuous groups. On-demand therapy with esomeprazole 40 mg appears to be sufficient for maintenance treatment in GERD patients.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Study design. Flow chart showed the recruitment of the study patients.
Figure 2
Figure 2
Percentages of patients that achieved alleviation of the intensity (Fig, 2a) and frequency (Fig. 2b) of heartburn in the on-demand and continuous group as determined by a Likert scale and frequent scales, respectively, at baseline and after 4 and 12 weeks of maintenance therapy. No significant between-group differences were found between percentages of patients that achieved alleviation of heartburn.
Figure 3
Figure 3
Percentages of patients that achieved alleviation of intensity (Fig. 3a) and frequency (Fig. 3b) of regurgitation in the on-demand and continuous groups as determined by a Likert scale and frequent scales, respectively, at baseline and after 4 and 12 weeks of maintenance therapy. No significant between-group differences were found between percentages of patients that achieved alleviation of regurgitation.

References

    1. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999;44:S1–6. - PMC - PubMed
    1. Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil 2011;17:14–27. - PMC - PubMed
    1. Moayyedi P, Talley N. Gastroesophageal reflux disease. Lancet 2006;367:2086–100. - PubMed
    1. Donnellan C, Sharma N, Preston C, et al. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;2:CD003245. - PubMed
    1. Nagahara A, Hojo M, Asaoka D, et al. Maintenance therapy of gastroesophageal reflux disease. Clin J Gastroenterol 2010;3:61–8. - PubMed

Publication types